Oncomine Precision Assay (OPA)

Comprehensive tumour profiling NGS panel

A next-generation sequencing (NGS) assay that profiles tumour DNA and RNA to direct treatment to the specific tumour type. The panel analyses 78 variants — including mutations, copy number variants (CNVs), and fusion variants — across 50 key cancer genes, including EGFR, ALK, BRAF, NTRK, ROS1, RET, KRAS, PIK3CA, and ERBB2. Results are delivered as a diagnostic and treatment interpretation, giving a thorough molecular profile to guide clinical decision-making.

• Tumour sample, collected by a surgeon or pathologist
• Supports both FFPE tissue and liquid biopsy samples
• 78 variants analysed: 45 mutations, 14 CNVs, 19 fusion variants
• 50-gene panel covering key oncology targets (EGFR, ALK, BRAF, NTRK, ROS1, RET, KRAS, PIK3CA, ERBB2, and more)
• Diagnostic and treatment-directing interpretation

• Supports treatment selection across multiple solid tumour types